AU782448B2 - Akt nucleic acids, polypeptides, and uses thereof - Google Patents

Akt nucleic acids, polypeptides, and uses thereof Download PDF

Info

Publication number
AU782448B2
AU782448B2 AU38802/00A AU3880200A AU782448B2 AU 782448 B2 AU782448 B2 AU 782448B2 AU 38802/00 A AU38802/00 A AU 38802/00A AU 3880200 A AU3880200 A AU 3880200A AU 782448 B2 AU782448 B2 AU 782448B2
Authority
AU
Australia
Prior art keywords
akt3
vector
nucleic acid
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU38802/00A
Other languages
English (en)
Other versions
AU3880200A (en
Inventor
Kenneth L. Clark
Kun Guo
Yuri D. Ivashchenko
Marco F. Pagnoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of AU3880200A publication Critical patent/AU3880200A/en
Assigned to AVENTIS PHARMACEUTICALS INC. reassignment AVENTIS PHARMACEUTICALS INC. Amend patent request/document other than specification (104) Assignors: AVENTIS PHARMACEUTICALS PRODUCTS INC.
Application granted granted Critical
Publication of AU782448B2 publication Critical patent/AU782448B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU38802/00A 1999-03-19 2000-03-14 Akt nucleic acids, polypeptides, and uses thereof Ceased AU782448B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19
US60/125108 1999-03-19
PCT/US2000/006574 WO2000056866A2 (en) 1999-03-19 2000-03-14 Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (2)

Publication Number Publication Date
AU3880200A AU3880200A (en) 2000-10-09
AU782448B2 true AU782448B2 (en) 2005-07-28

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38802/00A Ceased AU782448B2 (en) 1999-03-19 2000-03-14 Akt nucleic acids, polypeptides, and uses thereof

Country Status (18)

Country Link
EP (1) EP1144600B1 (enExample)
JP (1) JP4237945B2 (enExample)
KR (1) KR100700908B1 (enExample)
AT (1) ATE402995T1 (enExample)
AU (1) AU782448B2 (enExample)
BR (1) BR0009170A (enExample)
CA (1) CA2343074C (enExample)
CY (1) CY1108459T1 (enExample)
DE (1) DE60039677D1 (enExample)
DK (1) DK1144600T3 (enExample)
ES (1) ES2310515T3 (enExample)
HK (1) HK1041288B (enExample)
IL (4) IL141984A0 (enExample)
NO (1) NO20014537L (enExample)
PT (1) PT1144600E (enExample)
SI (1) SI1144600T1 (enExample)
WO (1) WO2000056866A2 (enExample)
ZA (1) ZA200108414B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
WO2000062605A1 (en) 1999-04-16 2000-10-26 Yale University eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING
WO2000077190A2 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
JPWO2003063905A1 (ja) * 2002-01-31 2005-05-26 株式会社東京大学Tlo 免疫疾患の予防又は治療剤
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
EP1661581A1 (en) * 2003-07-28 2006-05-31 Osaka Industrial Promotion Organization Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same
EP2599793A1 (en) * 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-phospho-akt antibodies
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
CN102985418B (zh) 2010-07-02 2015-09-09 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
ES2731602T3 (es) 2014-09-24 2019-11-18 Gilead Sciences Inc Métodos para tratar la enfermedad hepática
CA3100432C (en) 2014-12-23 2023-08-08 Gilead Sciences, Inc. Processes for preparing ask1 inhibitors
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
WO2020180886A1 (en) * 2019-03-04 2020-09-10 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the akt pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
DE69633186T2 (de) * 1995-11-16 2005-08-18 Novartis Ag Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
WO2000077190A2 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEM J 331, 299-308 *
KONISHI ET AL; (1995) BIOCHEM BIOPHYS RES COMM 216, 526-34 *

Also Published As

Publication number Publication date
EP1144600B1 (en) 2008-07-30
NO20014537D0 (no) 2001-09-18
DK1144600T3 (da) 2008-11-24
AU3880200A (en) 2000-10-09
DE60039677D1 (de) 2008-09-11
ATE402995T1 (de) 2008-08-15
PT1144600E (pt) 2008-10-10
WO2000056866A2 (en) 2000-09-28
CY1108459T1 (el) 2013-09-04
WO2000056866A9 (en) 2002-08-29
EP1144600A2 (en) 2001-10-17
SI1144600T1 (sl) 2008-12-31
IL141984A0 (en) 2002-03-10
BR0009170A (pt) 2002-04-30
IL145514A0 (en) 2002-06-30
HK1041288B (en) 2008-11-07
NO20014537L (no) 2001-10-31
JP2002539781A (ja) 2002-11-26
CA2343074C (en) 2010-09-21
WO2000056866A3 (en) 2001-02-15
KR20020011972A (ko) 2002-02-09
ZA200108414B (en) 2003-03-26
KR100700908B1 (ko) 2007-03-29
CA2343074A1 (en) 2000-09-28
JP4237945B2 (ja) 2009-03-11
HK1041288A1 (en) 2002-07-05
IL145514A (en) 2010-05-17
ES2310515T3 (es) 2009-01-16
IL190270A (en) 2012-12-31

Similar Documents

Publication Publication Date Title
US7989584B2 (en) AKT nucleic acids, polypeptides, and uses thereof
IL190270A (en) Use of 3AKT nucleic acids for the preparation of a drug for the treatment of cell death, treatment of myocardial infarction or injury due to blockage in the blood supply
AU773450B2 (en) Induction of vascular endothelial growth factor (VEGF) by the serine/threonine protein kinase AKT
AU4076800A (en) Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNF-alpha) signaling pathway
JP4548938B2 (ja) Mekk1(セリントレオニンキナーゼ)相互作用性fha(フォークヘッド結合ドメイン)タンパク質1(mif1)
MXPA01009431A (en) Akt nucleic acids, polypeptides, and uses thereof
US7332593B2 (en) Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNFα) signaling pathway
US6890733B1 (en) MEKK1 (serine threonine kinases)-interacting FHA (forkhead associated domain) protein 1 (M1F1)

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: AVENTIS PHARMACEUTICALS INC.

Free format text: FORMER NAME: AVENTIS PHARMACEUTICALS PRODUCTS INC.